The mechanism behind how a facultative enzyme governs tumour growth in prostate cancer patients has been detailed by researchers.

"It's known as Mnk, and although it appears not to be essential for normal cell maintenance, it's important for cancer growth," said Luc Furic, a postdoctoral researcher working with Dr. Nahum Sonenberg at McGill University's Goodman Cancer Research Centre and Department of Biochemistry.
This is a very significant finding because the body's chemical processes are highly complex and interrelated, meaning that targeting one cause of cancer often involves affecting the body's normal functions.
An important part of cancer research is about trying to find processes that can be inhibited or stopped without causing damages to normal tissue.
The chemical process Mnk uses is known as phosphorylation, and this process activates or inactivates the body's proteins, controlling mechanisms that can cause disease.
In this case, Mnk works with a protein known as eIF4E to synthesize proteins in the cell.
Advertisement
"The PTEN gene and its protein act as a tumour suppressor," explained Fred Saad, researcher at the CRCHUM and at Université de Montreal's Department of Surgery.
Advertisement
Source-ANI